Arab Board Oncology Part 1
Arab Board Medical Oncology Primary (Part 1) Written Exam (ABHS)
Targeted And ImmunotherapyEnglish
Exam overviewPractice session
Osimertinib is a 3rd-generation EGFR tyrosine kinase inhibitor (TKI) designed to overcome which specific secondary acquired resistance mutation that arises in patients treated with 1st-generation EGFR TKIs (gefitinib/erlotinib)?
Loading your practice session…